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Abstract
Autism, a pervasive neurodevelopmental disorder manifested by deficits in social behavior and interpersonal
communication, and by stereotyped, repetitive behaviors, is inexplicably biased towards males by a ratio of ,4:1, with
no clear understanding of whether or how the sex hormones may play a role in autism susceptibility. Here, we show that
male and female hormones differentially regulate the expression of a novel autism candidate gene, retinoic acid-related
orphan receptor-alpha (RORA) in a neuronal cell line, SH-SY5Y. In addition, we demonstrate that RORA transcriptionally
regulates aromatase, an enzyme that converts testosterone to estrogen. We further show that aromatase protein is
significantly reduced in the frontal cortex of autistic subjects relative to sex- and age-matched controls, and is strongly
correlated with RORA protein levels in the brain. These results indicate that RORA has the potential to be under both
negative and positive feedback regulation by male and female hormones, respectively, through one of its transcriptional
targets, aromatase, and further suggest a mechanism for introducing sex bias in autism.
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Introduction
Autism refers to a spectrum of neurodevelopmental disorders
with a prevalence of ,1:110 that are characterized by deficits in
social understanding and interactions, aberrant language devel-
opment and/or usage, and repetitive, stereotyped behaviors, often
with restricted interests[1,2]. The disorder is inexplicably biased
towards males by a ratio of at least 4:1, prompting theories that
fetal or perinatal exposure to elevated levels of male hormones
may increase susceptibility towards autism[3]. Despite some
evidence linking elevated fetal testosterone levels in amniotic fluid
to autistic symptomatology[4,5] and increasing rightward asym-
metry of the corpus callosum[6], (which is known to be aberrant in
autism[7]) and our own studies which have identified deregulated
genes involved in androgen biosynthesis as well as higher
testosterone levels in lymphoblastoid cells from autistic individuals
[8], no sex hormone-sensitive candidate genes for autism have
been reported. At present, there is still no clear understanding of
the molecular mechanisms through which the sex hormones may
play a role in autism susceptibility.
We have recently identified a novel autism candidate gene,
retinoic acid-related (RAR) orphan receptor-alpha (RORA)[9],
which is a hormone-dependent transcription factor. In brief, our
combined studies have demonstrated: a) reduced expression of
RORA in lymphoblastoid cell lines (LCL) derived from autistic
individuals[10,11]; b) increased methylation and reduced protein
expression of RORA in the LCL[9]; and c) decreased expression
of RORA protein in autistic brain[9]. Together, these results link
molecular changes in RORA in peripheral cells to molecular
pathology in the brain of autistic individuals. These findings are
particularly relevant to ASD as RORA is involved in several key
processes negatively impacted in autism, including Purkinje cell
differentiation[12], cerebellar development[13,14], protection of
neurons against oxidative stress[15], suppression of inflamma-
tion[16], and regulation of circadian rhythm[17]. Behavioral
studies on the RORA-deficient staggerer (RORA
+/sg) mouse,
primarily used as a model to study ataxia and dystonia[13],
further show that RORA is also associated with restricted
behaviors reminiscent of ASD, such as perseverative tenden-
cies[18], limited maze patrolling[19], anomalous object explora-
tion[20] as well as deficits in spatial learning[21]. Although there
are currently no reported studies on the social behaviors of staggerer
mice, it is clear that RORA is associated with at least some of the
symptomatology and pathology of ASD.
Here, we show that the level of RORA expression can be
regulated by both male and female hormones through their
respective receptors, and that one of its transcriptional targets is
CYP19A1 (aromatase), an enzyme responsible for the conversion of
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aromatase protein in brain tissues from autistic and nonautistic
donors correlates with the amount of RORA protein, with a
statistically significant reduction of both RORA and aromatase in
autistic tissues. We thus propose that in ASD, down-regulation of
RORA is exacerbated by a negative feedback mechanism involving
reduction of aromatase that can result in build-up of its substrate
testosterone which, in turn, can further suppress RORA expression.
Results
Male and female hormones oppositely regulate RORA
expression in human neuroblastoma cells
BecauseRORA is a hormone-dependent transcriptionfactor that
is involved in a variety of functions impacted in autism, we sought to
investigate the effects of both male and female hormones on RORA
expression. Inasmuch as estrogens are known to have neuroprotec-
tive effects on the brain and RORA has been reported to be
neuroprotective against oxidative stress [15] and inflammation[16],
we first treated the human neuroblastoma cell line SH-SY5Y with
different concentrations of 17b-estradiol, and measured RORA
expression by qRT-PCR analyses. The estradiol treatment
significantly enhanced RORA expression, and the greatest
upregulation (,15-fold) of RORA was observed when the cells
were treated with 1 nM estradiol (Fig. 1A). We also conducted a
time-course experiment to investigate changes in RORA expression
at different time points after estradiol exposure. The time-course
study revealed that RORA expression was highest at 2 hrs after
estradiol treatment, and the upregulation of RORA could be
observed as long as 24 hrs after the treatment (Fig. 1B).
Figure 1. Effect of sex hormones on RORA expression in SH-SY5Y cells. (A) Dose-response to estradiol. The cells were treated with 0.1, 1, or
10 nM 17b-estradiol (E2) for 2 hrs and RORA expression was measured by qRT-PCR analyses (n=3 per treatment group). (B) Time-course of response
to estradiol. The cells were treated with 1 nM 17b-estradiol and qRT-PCR analyses (n=3 per time point) were conducted to determine RORA
expression at different times after hormone addition. (C) Dose-response to DHT. The cells were treated with 0.1, 1, or 10 nM DHT for 2 hrs and RORA
expression was measured by qRT-PCR analyses (n=3 per treatment group). (D) Time-course of response to DHT. The cells were treated with 10 nM
DHT and qRT-PCR analyses (n=3 per time point) were conducted to determine RORA expression at different times after hormone addition. Error bars
indicate SEM (*P,0.05, **P,0.01, ***P,0.005, versus mock-treatment control).
doi:10.1371/journal.pone.0017116.g001
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influence RORA expression, dose-effect and time-course experi-
ments using dihydrotestosterone (DHT) were performed in the
same manner as the aforementioned estradiol treatment. Interest-
ingly, in contrast to estrogen treatment, DHT treatment caused a
decrease in RORA expression compared with mock treatment
(Fig. 1C). A time-course study showed that the greatest suppression
of RORA was observed between 2 and 4 hrs, and downregulation
of RORA could be observed as long as 24 hrs after DHT
treatment (Fig. 1D). This unexpected result (that is, decrease in
RORA expression) led us to investigate whether or not RORA
might be a transcriptional target of both estrogen receptor (ER)
and androgen receptor (AR) by chromatin immunoprecipitation
(ChIP)-PCR analyses.
RORA is a potential transcriptional target of androgen
and estrogen receptors
DHT and estradiol are known to exert their transcriptional
regulatory functions through androgen receptor (AR) and estrogen
receptor alpha (ERa), respectively. To investigate whether RORA
might be a direct transcriptional target of either AR or ERa,w e
first identified potential binding sites for AR and ERa within 10 kb
upstream of the RORA transcription start site using JASPAR,
PROMO 3.0, and SABioscience ChampionChIP Real-Time PCR
databases[22–24]. Three potential AR binding sites (namely ARbs
I-III) and four potential ERa binding sites (namely ERbs I-IV)
were selected for ChIP-qPCR analyses (Fig. 2A). The list of all
potential binding sites and their genomic locations is shown in
Table S1.
Neuroblastoma cells, treated with 1 nM DHT or 1 nM
estradiol, were employed for the ChIP assays using anti-AR or
anti-ERa antibody, respectively. Interestingly, the enrichment of
the AR binding sites in anti-AR-IP DNA was significantly
increased when the cells were treated with DHT, compared with
mock treatment (Fig. 2B). The highest enrichment was observed in
the ARbs-I region. Similarly, we found a significant increase in
enrichment of the ERa binding sites in anti-ERa-IP DNA when
the cells were treated with estradiol (Fig. 2C). The ERbs-II site
exhibited the greatest enrichment (,70-fold), compared with the
other potential ER binding sites. These data indicate that RORA
is likely a direct transcriptional target of both AR and ERa, with
DHT and estradiol treatment significantly increasing the binding
of AR and ER, respectively, to the RORA promoter region.
Aromatase is a transcriptional target of RORA
Aromatase (CYP19A1), a member of the cytochrome P450
family of proteins, is responsible for estradiol biosynthesis. This
protein is the key hydroxylating enzyme which converts
androstenedione to estrone and testosterone to estradiol. Aroma-
tase is therefore considered a crucial protein in regulating levels of
male and female sex hormones in various tissues, including
gonads, adipose tissue, placenta, and brain. Using the JASPAR,
PROMO3.0, and ChampionChIP databases, we found 3 potential
RORA binding sites (RORAbs I-III) within 2 kb upstream of the
aromatase gene (Fig. 3A, Table S1). Two sites, one of which is a
combination of adjacent sites II and III, were selected for ChIP-
qPCR analyses. To determine whether RORA could directly bind
to these potential binding sites on the aromatase gene, ChIP-
qPCR analyses were conducted using anti-RORA antibody. A
significant enrichment of the RORAbs-I region was observed in
the anti-RORA-IP DNA (Fig. 3B), indicating that aromatase is
likely to be a direct transcriptional target of RORA.
Functional analysis of RORA was conducted to further
demonstrate that aromatase is transcriptionally regulated by
RORA. Human neuroblastoma cells were transfected with a
pSG5.HA vector containing the DNA-binding and transactivation
sequence of RORA (pSG5.HA-RORA), and qRT-PCR analyses
were performed to determine the amount of RORA and
aromatase transcripts in the transfected cells 24 hrs after
transfection. A significant increase in RORA transcript level was
observed in the cells transfected with the plasmid, indicating that
the transfection was successful (Fig. 3C). Interestingly, overexpres-
sion of RORA was accompanied by a significant increase (,10-
fold) in aromatase transcript level (Fig. 3D). This finding thus
demonstrates that aromatase expression is regulated by RORA.
Aromatase protein is decreased and correlated with
RORA protein level in postmortem brain tissues of
autistic individuals
Our laboratory has recently demonstrated the reduction of
RORA protein in the frontal cortex and the cerebellum of autistic
subjects relative to that of control subjects by immunohistochem-
ical analyses of tissue arrays[9]. In this study, confocal immuno-
fluorescence analyses of tissue arrays containing postmortem
frontal cortex from autistic individuals and sex- and age-matched
controls were conducted to quantify the expression levels of
RORA and aromatase protein in the brain. The tissue arrays were
co-immunolabeled for RORA, aromatase, and the neuronal
marker MAP2, and then were counter-stained with DAPI to
visualize the nucleus of the cells. Notably, both RORA and
aromatase proteins were significantly reduced in frontal cortex
neurons from autistic subjects compared with those from sex- and
age-matched controls (Fig. 4A, B). Moreover, expression of
aromatase protein in the neurons was also strongly correlated
with RORA expression (R
2=0.915; Fig. 4C).
Discussion
The results of this study suggest that the expression of RORA is
inversely modulated by male and female sex hormones, with DHT
and estradiol increasing the binding of AR and ER, respectively, to
the RORA promoter region. Interestingly, estradiol enhances
RORA expression, whereas DHT represses expression of RORA.
The specific mechanism and circumstances through which AR
and ER regulate RORA in opposite directions are unknown and
require further study. Although these hormonal effects were
observed in the SH-SY5Y neuroblastoma cell line which is a
widely used neuronal cell model, this line may not replicate all
responses of primary neurons. Thus, it would also be important to
study the effects of sex hormones on RORA expression and
interactions in primary neurons, using an appropriate animal
model. In this respect, the accelerated Purkinje cell loss observed during
aging in male staggerer (RORA
+/sg) mice vs. female staggerer mice
supports the concept of interaction between the sex hormones and
RORA, with the male mice being more susceptible to RORA
deficiency [25]. By comparison, no gender-related differences in
the progression of Purkinje cell loss were observed in wild-type
(RORA
+/+) mice.
We also show that one of the transcriptional targets of RORA is
aromatase, which is a crucial enzyme in the biosynthesis of
estrogen from testosterone. It is noteworthy that both RORA and
aromatase proteins are decreased in the frontal cortex of autistic
subjects, and that the level of aromatase protein is strongly
correlated with the level of RORA protein in the brain tissues. We
therefore propose that the reduction of RORA observed in autism
is exacerbated by a negative feedback mechanism involving
decreased aromatase level, which further causes accumulation of
its substrate, testosterone, and reduction of its product, estradiol.
Male and Female Hormones in Autism
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positive feedback regulation of RORA expression as illustrated
in Fig. 5, which summarizes the principal findings of this study.
Thus, a deficiency in RORA in autistic brain is expected to be
further aggravated by increased levels of testosterone due to
suppression of aromatase, a transcriptional target of RORA.
These results provide a molecular mechanism whereby
testosterone may be increased in some cases of autism and further
Figure 2. RORA is a potential transcriptional target of both AR and ER. (A) Schematic diagram showing the upstream region of the RORA
gene (edited from the UCSC Genome Browser). Potential AR and ER binding sites are labeled (ARbs = AR potential binding site, ERbs = ER potential
binding site). (B) Chromatin Immunoprecipitation followed by qPCR (ChIP-qPCR) analyses of AR potential binding sites on the RORA gene promoter
region. Sonicated chromatin from SH-SY5Y cells treated with 1 nM DHT for 2 hrs was immunoprecipitated (IP) using anti-AR or IgG antibody. Parallel
samples were mock-treated with the hormone delivery vehicle, ethanol. The enrichment of each AR binding site in anti-AR-IP DNA was determined
by qPCR analyses (n=3), and normalized to the enrichment in IgG-IP DNA (control). Error bars indicate SEM (*P,0.01 versus mock-treatment control).
(C) ChIP-qPCR analyses of ERa potential binding sites on the RORA gene promoter region. Sonicated chromatin from SH-SY5Y cells treated with 1 nM
17b-estradiol (or vehicle) for 2 hrs was immunoprecipitated using anti-ERa or control IgG antibody. The enrichment of each ERa binding site in anti-
ERa-IP DNA was determined by qPCR analyses (n=3), and normalized to the enrichment in IgG-IP DNA. Error bars indicate SEM (
#Undetectable
amount of ERa binding sites in the mock-treatment control).
doi:10.1371/journal.pone.0017116.g002
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Indeed, RORA’s likely involvement in the balance between male
and female hormones in brain tissues through regulation of
aromatase transcription, coupled with its critical roles in Purkinje
cell differentiation and cerebellar development as well as in
neuroprotection against inflammation and oxidative stress,
explains at least some of the pathology observed in autism.
However, we note that not all samples from autistic individuals are
deficient in RORA, as demonstrated by our previous studies with
lymphoblastoid cell lines and brain tissues[9,10]. On the other
hand, we observed reductions in RORA in brain tissues from both
male and female subjects with ASD, suggesting that RORA
Figure 3. Aromatase is a potential transcriptional target of RORA. (A) Schematic diagram showing the upstream region of the aromatase
gene (edited from the UCSC Genome Browser). Potential RORA binding sites are labeled (RORAbs = RORA potential binding sites). Because sites II
and III are so close to each other, a single pair of primers was designed to cover both sites. (B) ChIP-qPCR analyses of potential binding sites for RORA
on the aromatase gene promoter region. Sonicated chromatin from SH-SY5Y cells was immunoprecipitated using anti-RORA or control IgG antibody.
The enrichment of each RORA binding site in anti-RORA-IP DNA was determined by qPCR analyses (n=3). Error bars indicate SEM (*P,0.05,
**P,0.001, versus the enrichment in IgG-IP DNA). Aromatase expression is enhanced by RORA overexpression. SH-SY5Y cells were
transfected with 1.25 mg or 2.50 mg pSG5.HA-RORA plasmid or empty plasmid for 24 hrs, and qRT-PCR analyses (n=3) were conducted to measure
RORA and aromatase expression (Mock = mock-treatment control, Neg = empty plasmid, RORA = pSG5.HA-RORA plasmid). (C) Relative quantity of
RORA transcript levels in RORA-transfected cells which is increased by more than a factor of 10
5 relative to the controls. (**P,0.001 versus the empty
plasmid control) (D) Relative quantity of aromatase transcript levels in RORA-transfected cells. Error bars indicate SEM (*P,0.05 versus the empty
plasmid control).
doi:10.1371/journal.pone.0017116.g003
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share a consensus binding site on DNA (AGGTCA) and
consequently common target genes. The existence of shared gene
targets may explain why females, with higher levels of estrogens,
are less susceptible to autism. That is, estrogens may not only
protect females against autism by increasing the level of RORA
expression, but also by inducing shared target genes of RORA
through ER, thus compensating in part for RORA deficiency.
In summary, we provide the first description of a candidate gene
for autism that is responsive to both male and female sex
hormones. We also demonstrate that a deficiency in this gene,
RORA, can potentially result not only in the increase in
testosterone levels, but also in further suppression of itself, through
negative feedback regulation which is mediated through its
transcriptional target, aromatase, which converts male hormones
to estrogens. Finally, we demonstrate the correlated decrease of
both RORA and aromatase protein levels in autistic brain, further
strengthening support for RORA as a critical candidate gene for
autism susceptibility.
Materials and Methods
Cell culture
The human neuroblastoma cells SH-SY5Y (ATCC, Manassas,
VA) were cultured in 1:1 Modified Eagle’s Medium (MEM) and
Ham’s F12 media (MediaTech, Manassas, VA) supplemented with
15% (v/v) fetal bovine serum (Atlanta Biological) and 1% penicillin/
streptomycin (P/S;MediaTech).Cells weremaintained at37uCwith
5% CO2, and split 1:2 every 3–4 days when the cells reached ,80%
confluency.Forharvesting,thecellsweretreatedwithtrypsin-EDTA
(MediaTech) for 2–3 min to release them from the surface of the
culture flask, followed by the addition of media to inactivate the
trypsin. The detached cells were then pelleted by spinning at 2,000
rpm for 5 min at 4uC and gently washed twice with cold PBS.
Figure 4. RORA and aromatase proteins are decreased in postmortem brain tissues from autistic subjects. A tissue array containing
postmortem frontal cortex specimen from 12 autistic individuals and 22 age- and sex-matched controls was co-immunolabeled for aromatase (red),
RORA (blue), and MAP2, and counterstained with DAPI to reveal nuclei (see Fig. S1 for example of quadruple staining). (A) Representative images
from confocal immunofluorescence analyses of the frontal cortex tissue arrays. Arrows mark neurons in the frontal cortex. Scale bars, 20 mm. F:
female; M: male; #’s indicate the respective ages of the subjects from whom the brain tissues were obtained. (B) Quantitative analyses of confocal
fluorescence images of RORA, aromatase, and DAPI. Frontal cortex neurons expressing MAP2 protein were selected according to its green
immunofluorescence (shown in Fig. S1), and fluorescence signal intensity for RORA, aromatase (ARO), and DAPI, in the neurons were extracted using
image analysis software and normalized by background subtraction. For each sample, ,40–50 neurons were selected for quantification of RORA and
aromatase fluorescence in a ‘‘sample blind’’ fashion such that the identities of the samples were unknown to the person performing the analyses.
Error bars indicate SEM (*P,0.05 versus the control samples). (C) Correlation analysis of RORA and aromatase protein expression in the frontal cortex
neurons.
doi:10.1371/journal.pone.0017116.g004
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For hormone treatment, SH-SY5Y cells were carefully washed
twice in situ with phenol red-free 1:1 DMEM/F12 media
(MediaTech) supplemented with 15% charcoal dextran-treated
serum (Atlanta Biologicals, Lawrenceville, GA) and 1% P/S, and
then cultured in the phenol red-free medium for 24 hours to
deplete the medium of exogenous hormones. Lyophilized 4,5a-
dihydrotestosterone (DHT) and 17b-estradiol (Sigma-Aldrich, St.
Louis, MO) were diluted with absolute ethanol to make 10 mM
DHT and 1 mM estradiol stock solutions which were then used
after appropriate dilutions for all hormone treatment experiments.
In the dose-response studies, the cells were treated with 0.1 nM,
1 nM, and 10 nM (final concentration) of DHT or estradiol for
2 hrs. In the time course study, cells were treated with 10 nM
DHT or 1 nM estradiol, and harvested at 1 hr, 2 hrs, 4 hrs, 8 hrs,
and 24 hrs after treatment. Cells treated with an equal volume of
vehicle (absolute ethanol) were used as a mock-treatment control
for both experiments.
Plasmid transfection
The DNA sequence coding for the DNA binding and
transcription activation sites of human RORA was cloned into
the pSG5.HA expression vector and confirmed by sequencing. To
enhance RORA expression in the SH-SY5Y neuroblastoma cells,
the plasmid was transfected into the cells using Lipofectamine
LTX and PLUS reagents (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. Briefly, SH-SY5Y cells were plated in
a 6-well culture plate containing complete growth media without
antibiotics (approximately 2.5610
5 cells per well) and incubated
for 24–36 hrs at 37uC and 5% CO2 until the cell density was 50–
60% confluent. The plasmid (1.25–2.50 mg) was diluted in 500 ml
of Opti-MEM I Reduced Serum Medium (Invitrogen) and 1.25 ml
of PLUS reagent was added to the diluted plasmid solution.
Lipofectamine LTX (25 ml) was then added to the plasmid solution
and incubated for 25 min at room temperature to form plasmid-
Lipofectamine LTX-PLUS complexes. The growth medium was
aspirated without disturbing the cells at the bottom of the plate,
and 500 ml of the plasmid-Lipofectamine LTX-PLUS complexes
were added directly to each well. The cells were then incubated
with the complexes at 37uC and 5% CO2 for 24 hrs before
harvest. For the negative control, the empty plasmid was
transfected into the cells in the same manner as the RORA
plasmid. Mock treatment without plasmid was also conducted to
serve as an additional negative control.
Quantitative RT-PCR analyses
Quantitative RT-PCR analyses were performed as described
[8]. Briefly, total RNA was isolated from the cells using the TRIzol
(Invitrogen) isolation method, and cDNA was synthesized using
iScript cDNA Synthesis Kit (BioRad, Hercules, CA) according to
the manufacturer’s protocols. The reaction was incubated at 25uC
for 5 min, followed by 42uC for 30 min, and ending with 85uC for
5 min. After reverse transcription, the cDNA reaction was diluted
to a volume of 50 ml with nuclease-free water and used as a
template for qPCR analyses. Real-time PCR analyses were
conducted using ABI Prism 7300 Sequence Detection System
(Applied Biosystems, Foster City, CA). Primers for qRT-PCR
analyses designed by Primer 3 are listed in Table S2.
Identification of potential binding sites for AR, ER, and
RORA
Putative binding sites for the transcription factors were
identified using PROMO 3.0, a web-based program that employs
the TRANSFAC database version 8.3 to construct specific binding
site weight matrices for prediction of transcription factor binding
sites [23,24]. The putative binding sites were then further
validated using JASPAR and ChampionChIP databases [22],
and carefully selected for ChIP-qPCR analyses. For AR and ER
binding sites on RORA gene, the DNA sequence of RORA plus
10 kb upstream was obtained from the UCSC Genome Browser
Database, and analyzed by PROMO3.0. A total of 3 AR binding
sites and 4 ER binding sites were selected for ChIP-qPCR
analyses. For RORA binding sites on the aromatase gene, the
DNA sequence of aromatase (CYP19A1) plus 10 kb upstream was
obtained from the UCSC Genome Browser and analyzed in the
same manner as the RORA DNA sequence. A total of 3 RORA
binding sites on aromatase were selected for ChIP-qPCR analyses.
All of the potential binding sites are listed in Table S1.
Chromatin immunoprecipitation-qPCR (ChIP-qPCR)
analyses
Chromatin immunoprecipitation (ChIP) was performed using
the Millipore EZ-ChIP Chromatin Immunoprecipitation Kit
(Millipore, Billerica, MA) according to the manufacturer’s
protocol. Briefly, the SH-SY5Y neuroblastoma cells were cultured
as previously described and treated with DHT or estradiol for
2 hrs. The cells were then treated with 37% formaldehyde for
exactly 10 min to crosslink the proteins to the DNA. The
crosslinked cells were transferred to a pre-chilled centrifuge tube,
and nuclear extraction was performed using the Active Motif
Nuclear Extract Kit (Active Motif, Carlsbad, CA) according to the
manufacturer’s protocol. Nuclear pellets were resuspended in the
SDS Lysis Buffer, and were sonicated on wet ice to shear the
chromatin to 200–1,000 bp. The sonication was conducted in a
cold room with 25 sets of 15-second pulses using a Heat Systems-
Ultrasonics W-380 sonicator (Heat Systems-Ultrasonics/Misonix,
Farmingdale, NY) set to 30% of maximum output power.
Sonicated chromatin was then divided into aliquots for 3–4
immunoprecipitation (IP) reactions.
Each IP reaction was conducted using 1 mg of mouse
monoclonal anti-AR (AR-441), mouse monoclonal anti-ERa
(ERa D-12), or rabbit polyclonal anti-RORA (RORA H-65)
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Sonicat-
ed chromatin was also immunoprecipitated with normal mouse
IgG or normal rabbit IgG antibodies (Santa Cruz Biotechnology)
to serve as negative controls. Anti-RNA polymerase II (Millipore)
was also included as a positive control. Immunoprecipitated DNA
(IP-DNA) was then reverse-crosslinked to separate it from the
Figure 5. A model for reciprocal hormonal effects on RORA. The
schematic illustrates a mechanism through which the observed
reduction in RORA in autistic brain may lead to increased testosterone
levels through downregulation of aromatase. Through AR, testosterone
negatively modulates RORA, whereas estrogen upregulates RORA
through ER.
doi:10.1371/journal.pone.0017116.g005
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(Millipore).
Real-Time qPCR analyses were conducted using an ABI Prism
7300 Sequence Detection System (Applied Biosystems) to measure
the enrichment of each putative transcription factor binding site in
the IP-DNA. Fold-enrichment of each binding site was determined
by normalizing the Ct value of the transcription factor binding site
in immunoprecipitated DNA with the Ct value of that transcrip-
tion factor binding site in IgG-IP DNA. Primer sequences for
qRT-PCR analyses designed by Primer 3 are listed in Table S2.
Confocal immunofluorescence microscopy
Human tissue arrays from Dr. Janine LaSalle’s laboratory
(University of California, Davis) were obtained through the Autism
Tissue Program (San Diego, CA). Each array contains 600 mm
diameter65 mm thick sections in triplicate from the BA9 region of
the frontal cortex from autistic individuals and age- and sex-
matched controls as well as from individuals with a variety of
developmental disorders as previously described [26]. Confocal
immunofluorescence analyses for RORA and aromatase proteins
were performed using the Alexa Fluor-conjugated secondary
antibody method of detection. Briefly, a tissue array was
deparaffinized in xylene and rehydrated using a dilution series of
100%, 95% and 75% ethanol. The array slide was then subjected
to heat-induced antigen retrieval by incubation in Tris-EDTA
buffer (10 nM Tris Base, 1 mM EDTA, 0.05% Tween 20, pH 9.0)
at 95uC for 25 minutes.
Rabbit polyclonal antibody (1:50 final dilution) against RORA
(4 mg/ml, Santa Cruz Biotechnology: sc-28612), goat polyclonal
antibody (1:50 dilution) against aromatase (4 mg/ml, Santa Cruz
Biotechnology: sc-14245), and mouse monoclonal antibody (1:100
dilution) against MAP2 (5 mg/ml, Invitrogen) were pooled and
added to the tissue array in a humidified chamber. After overnight
incubation at 4uC, unbound primary antibodies were removed by
washing the slide 3 times with PBS. Alexa Fluor 488-conjugated
donkey anti-mouse (1:200 final dilution), Alexa Fluor 546-
conjugated donkey anti-goat (1:200), and Alexa Fluor 647-
conjugated donkey anti-rabbit (1:200) secondary antibodies
(Invitrogen) were pooled and added to the slide for 45 min at
room temperature. The slide was then washed and incubated with
49,6 9-diamidino-2-phynylindole dihydrochloride (DAPI) for 5 min
at room temperature to counterstain the nuclei. The slide was
mounted using ProLong Gold antifade reagent (Invitrogen), and
left in the dark at room temperature for 24 hrs before imaging.
The fixed slide was imaged using a Zeiss LSM 710 confocal
microscope (Carl Zeiss, Thornwood, NY) with a 60X objective
lens. A total of 4 contiguous areas were scanned for each specimen,
and the images were collected using ZEN 2009 software (Carl
Zeiss). The same laser power and other scanning parameters were
maintained for all specimens. Fluorescence signals from Alexa
Fluor 546 (detecting aromatase) and from Alexa Fluor 647
(detecting RORA) are represented by red and blue pseudocolors,
respectively. The MAP2 fluorescence, which was used to select
neurons for RORA and aromatase quantification, was observed
using green pseudocolor and DAPI nuclear stain was represented
by gray (see Fig. S1).
Tissue images were coded with numbers and letters and
analyzed in blind fashion using Volocity software (PerkinElmer,
Waltham, MA). For each specimen, 40–50 frontal cortex neurons
with distinct expression of MAP2 fluorescence and nuclear
staining were selected for quantification of RORA and aromatase
fluorescence intensities. The mean fluorescence intensity values
from all neurons in each specimen were averaged and normalized
by background subtraction.
Statistical analyses
ANOVA analyses were performed to determine significance of
the differences in expression levels between the hormonally-treated
and untreated samples as well as the fluorescence intensities
between the autistic and the control groups.
Supporting Information
Table S1 Potential transcription factor binding sites for
AR, ER, and RORA.
(DOC)
Table S2 Primer sequences for RT-qPCR and qPCR
analyses.
(DOC)
Figure S1 Confocal fluorescence images of brain tissues
stained for A) nuclei, B) MAP2, C) Aromatase, and D)
RORA.
(TIF)
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